
Global Inactivated Influenza Virus Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031
Description
Summary
According to APO Research, The global Inactivated Influenza Virus Vaccine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Inactivated Influenza Virus Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Inactivated Influenza Virus Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Inactivated Influenza Virus Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Inactivated Influenza Virus Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Inactivated Influenza Virus Vaccine include CSL, Zhejiang Tian Yuan Biopharmaceutical Co., Ltd, Changchun Institute of Biological Products Co., Ltd, Shanghai Institute of Biological Products Co., Ltd, Johnson & Johnson, Mylan, Lanzhou Institute of Biological Products Co., Ltd, Jiangsu Kangrun Biotechnology Co., Ltd and Jiangsu Jindik Biotechnology Co., Ltd, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Inactivated Influenza Virus Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Inactivated Influenza Virus Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Inactivated Influenza Virus Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Inactivated Influenza Virus Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Inactivated Influenza Virus Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Inactivated Influenza Virus Vaccine sales, projected growth trends, production technology, application and end-user industry.
Inactivated Influenza Virus Vaccine Segment by Company
CSL
Zhejiang Tian Yuan Biopharmaceutical Co., Ltd
Changchun Institute of Biological Products Co., Ltd
Shanghai Institute of Biological Products Co., Ltd
Johnson & Johnson
Mylan
Lanzhou Institute of Biological Products Co., Ltd
Jiangsu Kangrun Biotechnology Co., Ltd
Jiangsu Jindik Biotechnology Co., Ltd
Pfizer
Hualan Bio Vaccines Co., Ltd
GSK
Dalian Yalifeng Biopharmaceutical Co., Ltd
Beijing Kexing Biological Products Co., Ltd
Emmi Chengxin Biopharmaceutical Co., Ltd
AstraZeneca
Sanofi Pasteur
Inactivated Influenza Virus Vaccine Segment by Type
Whole Virus Vaccine
Subunit Vaccine
Inactivated Influenza Virus Vaccine Segment by Application
Hospital
Clinic
Inactivated Influenza Virus Vaccine Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Inactivated Influenza Virus Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Inactivated Influenza Virus Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Inactivated Influenza Virus Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Inactivated Influenza Virus Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Inactivated Influenza Virus Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Inactivated Influenza Virus Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Inactivated Influenza Virus Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
According to APO Research, The global Inactivated Influenza Virus Vaccine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Inactivated Influenza Virus Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Inactivated Influenza Virus Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Inactivated Influenza Virus Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Inactivated Influenza Virus Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Inactivated Influenza Virus Vaccine include CSL, Zhejiang Tian Yuan Biopharmaceutical Co., Ltd, Changchun Institute of Biological Products Co., Ltd, Shanghai Institute of Biological Products Co., Ltd, Johnson & Johnson, Mylan, Lanzhou Institute of Biological Products Co., Ltd, Jiangsu Kangrun Biotechnology Co., Ltd and Jiangsu Jindik Biotechnology Co., Ltd, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Inactivated Influenza Virus Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Inactivated Influenza Virus Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Inactivated Influenza Virus Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Inactivated Influenza Virus Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Inactivated Influenza Virus Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Inactivated Influenza Virus Vaccine sales, projected growth trends, production technology, application and end-user industry.
Inactivated Influenza Virus Vaccine Segment by Company
CSL
Zhejiang Tian Yuan Biopharmaceutical Co., Ltd
Changchun Institute of Biological Products Co., Ltd
Shanghai Institute of Biological Products Co., Ltd
Johnson & Johnson
Mylan
Lanzhou Institute of Biological Products Co., Ltd
Jiangsu Kangrun Biotechnology Co., Ltd
Jiangsu Jindik Biotechnology Co., Ltd
Pfizer
Hualan Bio Vaccines Co., Ltd
GSK
Dalian Yalifeng Biopharmaceutical Co., Ltd
Beijing Kexing Biological Products Co., Ltd
Emmi Chengxin Biopharmaceutical Co., Ltd
AstraZeneca
Sanofi Pasteur
Inactivated Influenza Virus Vaccine Segment by Type
Whole Virus Vaccine
Subunit Vaccine
Inactivated Influenza Virus Vaccine Segment by Application
Hospital
Clinic
Inactivated Influenza Virus Vaccine Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Inactivated Influenza Virus Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Inactivated Influenza Virus Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Inactivated Influenza Virus Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Inactivated Influenza Virus Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Inactivated Influenza Virus Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Inactivated Influenza Virus Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Inactivated Influenza Virus Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
Table of Contents
197 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Inactivated Influenza Virus Vaccine Market Size, 2020 VS 2024 VS 2031
- 1.3 Global Inactivated Influenza Virus Vaccine Market Size Estimates and Forecasts (2020-2031)
- 1.4 Global Inactivated Influenza Virus Vaccine Sales Estimates and Forecasts (2020-2031)
- 1.5 Global Inactivated Influenza Virus Vaccine Market Average Price (2020-2031)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 2 Global Inactivated Influenza Virus Vaccine Market Dynamics
- 2.1 Inactivated Influenza Virus Vaccine Industry Trends
- 2.2 Inactivated Influenza Virus Vaccine Industry Drivers
- 2.3 Inactivated Influenza Virus Vaccine Industry Opportunities and Challenges
- 2.4 Inactivated Influenza Virus Vaccine Industry Restraints
- 3 Inactivated Influenza Virus Vaccine Market by Manufacturers
- 3.1 Global Inactivated Influenza Virus Vaccine Revenue by Manufacturers (2020-2025)
- 3.2 Global Inactivated Influenza Virus Vaccine Sales by Manufacturers (2020-2025)
- 3.3 Global Inactivated Influenza Virus Vaccine Average Sales Price by Manufacturers (2020-2025)
- 3.4 Global Inactivated Influenza Virus Vaccine Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
- 3.5 Global Inactivated Influenza Virus Vaccine Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Inactivated Influenza Virus Vaccine Manufacturers, Product Type & Application
- 3.7 Global Inactivated Influenza Virus Vaccine Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Inactivated Influenza Virus Vaccine Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Inactivated Influenza Virus Vaccine Players Market Share by Revenue in 2024
- 3.8.3 2024 Inactivated Influenza Virus Vaccine Tier 1, Tier 2, and Tier 3
- 4 Inactivated Influenza Virus Vaccine Market by Type
- 4.1 Inactivated Influenza Virus Vaccine Type Introduction
- 4.1.1 Whole Virus Vaccine
- 4.1.2 Subunit Vaccine
- 4.2 Global Inactivated Influenza Virus Vaccine Sales by Type
- 4.2.1 Global Inactivated Influenza Virus Vaccine Sales by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Inactivated Influenza Virus Vaccine Sales by Type (2020-2031)
- 4.2.3 Global Inactivated Influenza Virus Vaccine Sales Market Share by Type (2020-2031)
- 4.3 Global Inactivated Influenza Virus Vaccine Revenue by Type
- 4.3.1 Global Inactivated Influenza Virus Vaccine Revenue by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Inactivated Influenza Virus Vaccine Revenue by Type (2020-2031)
- 4.3.3 Global Inactivated Influenza Virus Vaccine Revenue Market Share by Type (2020-2031)
- 5 Inactivated Influenza Virus Vaccine Market by Application
- 5.1 Inactivated Influenza Virus Vaccine Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.2 Global Inactivated Influenza Virus Vaccine Sales by Application
- 5.2.1 Global Inactivated Influenza Virus Vaccine Sales by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Inactivated Influenza Virus Vaccine Sales by Application (2020-2031)
- 5.2.3 Global Inactivated Influenza Virus Vaccine Sales Market Share by Application (2020-2031)
- 5.3 Global Inactivated Influenza Virus Vaccine Revenue by Application
- 5.3.1 Global Inactivated Influenza Virus Vaccine Revenue by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Inactivated Influenza Virus Vaccine Revenue by Application (2020-2031)
- 5.3.3 Global Inactivated Influenza Virus Vaccine Revenue Market Share by Application (2020-2031)
- 6 Global Inactivated Influenza Virus Vaccine Sales by Region
- 6.1 Global Inactivated Influenza Virus Vaccine Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Inactivated Influenza Virus Vaccine Sales by Region (2020-2031)
- 6.2.1 Global Inactivated Influenza Virus Vaccine Sales by Region (2020-2025)
- 6.2.2 Global Inactivated Influenza Virus Vaccine Sales Forecasted by Region (2025-2030)
- 6.3 North America
- 6.3.1 North America Inactivated Influenza Virus Vaccine Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.3.2 North America Inactivated Influenza Virus Vaccine Sales by Country (2020-2031)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Inactivated Influenza Virus Vaccine Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.4.2 Europe Inactivated Influenza Virus Vaccine Sales by Country (2020-2031)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Inactivated Influenza Virus Vaccine Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.5.2 Asia Pacific Inactivated Influenza Virus Vaccine Sales by Country (2020-2031)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Inactivated Influenza Virus Vaccine Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.6.2 South America, Middle East and Africa Inactivated Influenza Virus Vaccine Sales by Country (2020-2031)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
- 7 Global Inactivated Influenza Virus Vaccine Revenue by Region
- 7.1 Global Inactivated Influenza Virus Vaccine Revenue by Region
- 7.1.1 Global Inactivated Influenza Virus Vaccine Revenue by Region: 2020 VS 2024 VS 2031
- 7.1.2 Global Inactivated Influenza Virus Vaccine Revenue by Region (2020-2025)
- 7.1.3 Global Inactivated Influenza Virus Vaccine Revenue by Region (2026-2031)
- 7.1.4 Global Inactivated Influenza Virus Vaccine Revenue Market Share by Region (2020-2031)
- 7.2 North America
- 7.2.1 North America Inactivated Influenza Virus Vaccine Revenue (2020-2031)
- 7.2.2 North America Inactivated Influenza Virus Vaccine Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.3 Europe
- 7.3.1 Europe Inactivated Influenza Virus Vaccine Revenue (2020-2031)
- 7.3.2 Europe Inactivated Influenza Virus Vaccine Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Inactivated Influenza Virus Vaccine Revenue (2020-2031)
- 7.4.2 Asia-Pacific Inactivated Influenza Virus Vaccine Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Inactivated Influenza Virus Vaccine Revenue (2020-2031)
- 7.5.2 South America, Middle East and Africa Inactivated Influenza Virus Vaccine Revenue Share by Country: 2020 VS 2024 VS 2031
- 8 Company Profiles
- 8.1 CSL
- 8.1.1 CSL Comapny Information
- 8.1.2 CSL Business Overview
- 8.1.3 CSL Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.1.4 CSL Inactivated Influenza Virus Vaccine Product Portfolio
- 8.1.5 CSL Recent Developments
- 8.2 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd
- 8.2.1 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Comapny Information
- 8.2.2 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Business Overview
- 8.2.3 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.2.4 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
- 8.2.5 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Recent Developments
- 8.3 Changchun Institute of Biological Products Co., Ltd
- 8.3.1 Changchun Institute of Biological Products Co., Ltd Comapny Information
- 8.3.2 Changchun Institute of Biological Products Co., Ltd Business Overview
- 8.3.3 Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.3.4 Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
- 8.3.5 Changchun Institute of Biological Products Co., Ltd Recent Developments
- 8.4 Shanghai Institute of Biological Products Co., Ltd
- 8.4.1 Shanghai Institute of Biological Products Co., Ltd Comapny Information
- 8.4.2 Shanghai Institute of Biological Products Co., Ltd Business Overview
- 8.4.3 Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.4.4 Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
- 8.4.5 Shanghai Institute of Biological Products Co., Ltd Recent Developments
- 8.5 Johnson & Johnson
- 8.5.1 Johnson & Johnson Comapny Information
- 8.5.2 Johnson & Johnson Business Overview
- 8.5.3 Johnson & Johnson Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.5.4 Johnson & Johnson Inactivated Influenza Virus Vaccine Product Portfolio
- 8.5.5 Johnson & Johnson Recent Developments
- 8.6 Mylan
- 8.6.1 Mylan Comapny Information
- 8.6.2 Mylan Business Overview
- 8.6.3 Mylan Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.6.4 Mylan Inactivated Influenza Virus Vaccine Product Portfolio
- 8.6.5 Mylan Recent Developments
- 8.7 Lanzhou Institute of Biological Products Co., Ltd
- 8.7.1 Lanzhou Institute of Biological Products Co., Ltd Comapny Information
- 8.7.2 Lanzhou Institute of Biological Products Co., Ltd Business Overview
- 8.7.3 Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.7.4 Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
- 8.7.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
- 8.8 Jiangsu Kangrun Biotechnology Co., Ltd
- 8.8.1 Jiangsu Kangrun Biotechnology Co., Ltd Comapny Information
- 8.8.2 Jiangsu Kangrun Biotechnology Co., Ltd Business Overview
- 8.8.3 Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.8.4 Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
- 8.8.5 Jiangsu Kangrun Biotechnology Co., Ltd Recent Developments
- 8.9 Jiangsu Jindik Biotechnology Co., Ltd
- 8.9.1 Jiangsu Jindik Biotechnology Co., Ltd Comapny Information
- 8.9.2 Jiangsu Jindik Biotechnology Co., Ltd Business Overview
- 8.9.3 Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.9.4 Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
- 8.9.5 Jiangsu Jindik Biotechnology Co., Ltd Recent Developments
- 8.10 Pfizer
- 8.10.1 Pfizer Comapny Information
- 8.10.2 Pfizer Business Overview
- 8.10.3 Pfizer Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.10.4 Pfizer Inactivated Influenza Virus Vaccine Product Portfolio
- 8.10.5 Pfizer Recent Developments
- 8.11 Hualan Bio Vaccines Co., Ltd
- 8.11.1 Hualan Bio Vaccines Co., Ltd Comapny Information
- 8.11.2 Hualan Bio Vaccines Co., Ltd Business Overview
- 8.11.3 Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.11.4 Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
- 8.11.5 Hualan Bio Vaccines Co., Ltd Recent Developments
- 8.12 GSK
- 8.12.1 GSK Comapny Information
- 8.12.2 GSK Business Overview
- 8.12.3 GSK Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.12.4 GSK Inactivated Influenza Virus Vaccine Product Portfolio
- 8.12.5 GSK Recent Developments
- 8.13 Dalian Yalifeng Biopharmaceutical Co., Ltd
- 8.13.1 Dalian Yalifeng Biopharmaceutical Co., Ltd Comapny Information
- 8.13.2 Dalian Yalifeng Biopharmaceutical Co., Ltd Business Overview
- 8.13.3 Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.13.4 Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
- 8.13.5 Dalian Yalifeng Biopharmaceutical Co., Ltd Recent Developments
- 8.14 Beijing Kexing Biological Products Co., Ltd
- 8.14.1 Beijing Kexing Biological Products Co., Ltd Comapny Information
- 8.14.2 Beijing Kexing Biological Products Co., Ltd Business Overview
- 8.14.3 Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.14.4 Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
- 8.14.5 Beijing Kexing Biological Products Co., Ltd Recent Developments
- 8.15 Emmi Chengxin Biopharmaceutical Co., Ltd
- 8.15.1 Emmi Chengxin Biopharmaceutical Co., Ltd Comapny Information
- 8.15.2 Emmi Chengxin Biopharmaceutical Co., Ltd Business Overview
- 8.15.3 Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.15.4 Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
- 8.15.5 Emmi Chengxin Biopharmaceutical Co., Ltd Recent Developments
- 8.16 AstraZeneca
- 8.16.1 AstraZeneca Comapny Information
- 8.16.2 AstraZeneca Business Overview
- 8.16.3 AstraZeneca Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.16.4 AstraZeneca Inactivated Influenza Virus Vaccine Product Portfolio
- 8.16.5 AstraZeneca Recent Developments
- 8.17 Sanofi Pasteur
- 8.17.1 Sanofi Pasteur Comapny Information
- 8.17.2 Sanofi Pasteur Business Overview
- 8.17.3 Sanofi Pasteur Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.17.4 Sanofi Pasteur Inactivated Influenza Virus Vaccine Product Portfolio
- 8.17.5 Sanofi Pasteur Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Inactivated Influenza Virus Vaccine Value Chain Analysis
- 9.1.1 Inactivated Influenza Virus Vaccine Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Inactivated Influenza Virus Vaccine Production Mode & Process
- 9.2 Inactivated Influenza Virus Vaccine Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Inactivated Influenza Virus Vaccine Distributors
- 9.2.3 Inactivated Influenza Virus Vaccine Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.